LISATA THERAPEUTICS, INC. — Director's Dealing 2016

Jun 23, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Caladrius Biosciences, Inc. (CLBS)
CIK: 0000320017
Period of Report: 2016-06-22

Reporting Person: Pecora Andrew L (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-06-22	Common Stock	A	7500	—	Acquired	393784	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-06-22	Options to Purchase Common Stock	$0.516	A	12500	Acquired	2026-06-22	Common Stock (12500)	Direct

Footnotes

F1: Represents 7,500 shares of restricted stock granted under the Issuer's 2015 Equity Compensation Plan that will vest on June 22, 2017.

F2: Includes 9,000 shares of unvested restricted stock granted under the Issuer's 2015 Equity Compensation Plan that will vest on January 25, 2017 and 7,500 shares of unvested restricted stock granted under the Issuer's 2015 Equity Compensation Plan that will vest on June 22, 2017.